We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Novel breast cancer treatment leads to hyperglycaemia.
- Authors
Bass, I. R.; Tiersten, A.; Trlica, K.; Ryncarz, A.; Adler, B.; Gallagher, E. J.
- Abstract
The article presents a case study of a 66-year-old woman with pre-diabetes and hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer was started on fulvestrant, and referred to endocrinology prior to initiation of alpelisib. Because of anticipated possible hyperglycaemia, and the woman's reluctance to start fingerstick glucose monitoring, a Continuous Glucose Monitor (CGM) was prescribed for safety.
- Subjects
ANTINEOPLASTIC agents; BLOOD sugar monitoring; BREAST tumors; CANCER chemotherapy; HYPERGLYCEMIA; METASTASIS; PROTEIN kinase inhibitors
- Publication
Diabetic Medicine, 2020, Vol 37, Issue 5, p893
- ISSN
0742-3071
- Publication type
Case Study
- DOI
10.1111/dme.14281